[Assessment of the formation of antibodies to interferon in patients with juvenile respiratory papillomatosis on interferon therapy].
Children with juvenile respiratory papillomatosis given alpha 2-INF had antibodies to alpha 2-INF in 67.7% of cases. In children treated with intramuscular recombinant alpha 2-INF (reaferon) alone antibodies to INF occurred in 92.3% of patients. The proportion of such patients fell to 28.5% if the children used recombinant alpha 2-INF as rectal suppositories viferon. The level of the antibodies in 4-48 hours decreased 2 times maximally and returned to the baseline on day 3 since intramuscular injection of alpha 2-INF. It is stated that interferon therapy had a positive effect on juvenile respiratory papillomatosis. Antibodies to INF had no negative effects on the treatment results.
Kol'tsov
V D
VD
Chireshkin
D G
DG
Onufrieva
E K
EK
Nurmukhametov
R Kh
RKh
Malinovskaia
V V
VV
Ershov
F I
FI
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000293:Adolescent; D000906:Antibodies / Q000032:analysis*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007273:Injections, Intramuscular; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007372:Interferons / Q000276:immunology*; D007822:Laryngeal Neoplasms / Q000276:immunology / Q000628:therapy*; D010212:Papilloma / Q000276:immunology / Q000628:therapy*; D011994:Recombinant Proteins; D013488:Suppositories
D000276:Adjuvants, Immunologic; D000906:Antibodies; D000970:Antineoplastic Agents; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D013488:Suppositories; D007372:Interferons
Otsenka obrazovaniia antitel k interferonu u bol'nykh iuvenilnym respiratornym papillomatozom pri interferonoterapii.